Literature DB >> 16230379

Ku86 modulates DNA topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells.

Shyh-Jen Shih1, Tara Erbele, Allan Y Chen.   

Abstract

Ku86 is an integral component of the nonhomologous end-joining (NHEJ) pathway of cellular double-strand break repair. In the current study, we investigated the role of Ku86 in DNA topoisomerase I-mediated radiosensitization induced by camptothecin in mammalian cells. Interestingly, as examined by clonogenic survival assay, a 30-minute camptothecin treatment induced significantly higher levels of radiosensitization in the Ku86-deficient Chinese hamster ovary xrs-6 cells than in the hamster Ku86-complemented xrs-6+hamKu86 cells, albeit exhibiting similar drug toxicity in these two cell lines. To confirm these findings, similar studies were conducted in two pairs of transfectant sublines established from the Ku86-deficient Chinese hamster lung fibroblast XR-V15B cells. Compared with the vector-alone sublines, radiation resistance was restored in the human Ku86-complemented sublines without alteration of cell cycle distributions. Again, significantly higher levels of camptothecin-induced radiosensitization were observed in the vector-alone sublines than in the Ku86-complemented XR-V15B sublines. In contrast, camptothecin treatments, ranging from 0.5 to 24 hours, induced similar cytotoxicities in both vector-alone and Ku86-complemented sublines. Because neither the DNA-damaging etoposide and cisplatin nor the tubulin-binder vinblastine induced enhanced levels of radiosensitization in the Ku86-deficient cells, Ku86 seems to uniquely affect topoisomerase I-mediated radiosensitization induced by camptothecin. Furthermore, cotreatment with DNA replication inhibitor aphidicolin abolished both camptothecin-induced cytotoxicity and radiosensitization in the vector-alone, as well as the Ku86-complemented subline cells, indicating both events are initiated by replication-dependent topoisomerase I-mediated DNA damages. Taken together, our data show a novel role of Ku86 in modulating topoisomerase I-mediated radiosensitization, but not cytotoxicity, in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16230379     DOI: 10.1158/0008-5472.CAN-05-2387

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Bcl2 negatively regulates DNA double-strand-break repair through a nonhomologous end-joining pathway.

Authors:  Qinhong Wang; Fengqin Gao; W Stratford May; Yangde Zhang; Tammy Flagg; Xingming Deng
Journal:  Mol Cell       Date:  2008-02-29       Impact factor: 17.970

2.  DNA topoisomerase I drugs and radiotherapy for lung cancer.

Authors:  Allan Y Chen; Patricia M T Chen; Yi-Jen Chen
Journal:  J Thorac Dis       Date:  2012-08       Impact factor: 2.895

3.  Siah1 proteins enhance radiosensitivity of human breast cancer cells.

Authors:  Hai-Tao He; Emmanouil Fokas; An You; Rita Engenhart-Cabillic; Han-Xiang An
Journal:  BMC Cancer       Date:  2010-08-03       Impact factor: 4.430

4.  Identification of Novel Proteins Co-Purifying with Cockayne Syndrome Group B (CSB) Reveals Potential Roles for CSB in RNA Metabolism and Chromatin Dynamics.

Authors:  Serena Nicolai; Silvia Filippi; Manuela Caputo; Lubos Cipak; Juraj Gregan; Gustav Ammerer; Mattia Frontini; Daniela Willems; Giorgio Prantera; Adayabalam S Balajee; Luca Proietti-De-Santis
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

5.  Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.

Authors:  Koji Ando; Ankur K Shah; Vibhu Sachdev; Benjamin P Kleinstiver; Julian Taylor-Parker; Moira M Welch; Yiheng Hu; Ravi Salgia; Forest M White; Jeffrey D Parvin; Al Ozonoff; Lucia E Rameh; J Keith Joung; Ajit K Bharti
Journal:  Oncotarget       Date:  2017-07-04

Review 6.  Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

Authors:  Maria I Del Olmo-García; Stefan Prado-Wohlwend; Pilar Bello; Angel Segura; Juan F Merino-Torres
Journal:  Cancers (Basel)       Date:  2022-01-24       Impact factor: 6.639

7.  Combination Strategies to Improve Targeted Radionuclide Therapy.

Authors:  Tiffany G Chan; Edward O'Neill; Christine Habjan; Bart Cornelissen
Journal:  J Nucl Med       Date:  2020-10-09       Impact factor: 10.057

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.